Lantheus Holdings, Inc. (LNTH)

NasdaqGM Currently down 1.03 (-0.98%) in today's trading session

1 member of Congress has disclosed 4 trades in Lantheus Holdings, Inc. (LNTH) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 28 January 2025. Aggregate disclosed activity totals roughly $32K in purchases (midpoint estimates from bracketed disclosure amounts).

Lantheus Holdings, Inc. is currently trading at $103.58, positioned at 87% of its 52-week range ($47.25 – $111.86).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$103.58
24h Change
-1.03 (-0.98%)
52 Week Range
$47.25$111.86
View on NASDAQ

Lantheus Holdings, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for LNTH

Select to highlight on chart
4 transactions
Compliance: 100%
Gilbert Cisneros28 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros13 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros8 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros7 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$6.74B

Volume

354.1K

Beta

-0.06

P/E Ratio

17.35

Fundamentals

EPS

$5.97

Div. Yield

Open

$103.59

Day Range

$101.34 — $104.70

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ · USD
Country
US
CEO
Mary Anne Heino
IPO Date
2015-06-25

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis an...

Earnings

Next Report

Q2 2026

5 Aug

EPS Est.

$1.33

Rev. Est.

$363M

Days Until

13

Recent Quarters

Q1 20267 May
EPS$1.46
Beat 16.8%
Q4 202526 Feb
EPS$1.67
Beat 41.5%
Q3 20256 Nov
EPS$1.27
Beat 0.0%
Q2 20256 Aug
EPS$1.57
Miss 4.3%
Q1 20257 May
EPS$1.53
Miss 8.9%
Q4 202426 Feb
EPS$1.59
Beat 0.6%
Q3 20246 Nov
EPS$1.70
Beat 9.0%
Q2 202431 Jul
EPS$1.80
Miss 1.6%
Q1 20242 May
EPS$1.69
Beat 9.7%
Q4 202322 Feb
EPS$1.75
Beat 20.7%
Q3 20232 Nov
EPS$1.47
Beat 11.4%
Q2 20233 Aug
EPS$1.54
Beat 17.6%
Q1 20234 May
EPS$1.47
Beat 13.9%
Q4 202223 Feb
EPS$1.37
Beat 42.7%
Q3 20223 Nov
EPS$0.99
Beat 19.3%
Q2 20224 Aug
EPS$0.89
Beat 27.1%
Q1 202229 Apr
EPS$0.97
Beat 110.9%
Q4 202124 Feb
EPS$0.25
Beat 47.1%
Q3 20214 Nov
EPS$0.08
Beat 33.3%
Q2 202128 Jul
EPS$0.11
Beat 120.0%
Q1 20214 May
EPS$0.05
Beat 576.6%
Q4 202025 Feb
EPS$0.07
Beat 483.3%
Q3 20205 Nov
EPS$0.04
Beat 332.4%
Q2 202030 Jul
EPS$0.10
Beat 60.6%
Q1 202030 Apr
EPS$0.36
Beat 33.3%
Q4 201925 Feb
EPS$0.34
Beat 13.3%
Q3 201931 Oct
EPS$0.28
Beat 12.0%
Q2 201925 Jul
EPS$0.27
Beat 0.0%
Q1 201930 Apr
EPS$0.28
Beat 12.0%
Q4 201819 Feb
EPS$0.29
Beat 93.3%
Q3 201830 Oct
EPS$0.24
Beat 33.3%
Q2 20181 Aug
EPS$0.26
Beat 18.2%
Q1 20182 May
EPS$0.22
Beat 0.0%
Q4 201726 Feb
EPS$0.12
Miss 25.0%
Q3 20172 Nov
EPS$0.24
Beat 14.3%
Q2 20171 Aug
EPS$0.34
Beat 47.8%
Q1 20172 May
EPS$0.28
Beat 47.4%
Q4 201621 Feb
EPS$0.18
Beat 38.5%
Q3 20161 Nov
EPS$0.15
Beat 114.3%
Q2 20164 Aug
EPS$0.24
Beat 300.0%
Q1 20163 May
EPS$0.15
Beat 150.0%
Q4 201522 Feb
EPS$0.13
Beat 450.9%
Q3 20154 Nov
EPS$0.18
Beat 318.6%
Q2 20154 Aug
EPS$0.05
Beat 135.7%
Q1 201526 Jun
EPS$0.01
Q4 201431 Mar
EPS$0.02
Q2 201430 Sept
EPS$-0.05
Q1 201430 Jun
EPS$-0.06
Q4 201331 Mar
EPS$-0.07
Q3 201331 Dec
EPS$-0.47
Q2 201330 Sept
EPS$-0.57
Q1 201330 Jun
EPS$-0.54
Q4 201231 Mar
EPS$-1.10
Q3 201231 Dec
EPS$-0.53

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

AAPL

Apple Inc.

22
$320.76-5.13 (-1.57%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

WBI

WaterBridge Infrastructure LLC

17
$35.51-0.70 (-1.93%)
Energy
Held by same politician
1 politician
View Stock

SPY

State Street SPDR S&P 500 ETF Trust

17
$736.99-10.42 (-1.39%)
Financial Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about LNTH

Which members of Congress have traded LNTH?
1 member of Congress has disclosed 4 trade in Lantheus Holdings, Inc. (LNTH) under the STOCK Act: Gilbert Cisneros.
When was LNTH most recently disclosed by Congress?
The most recent LNTH disclosure was a purchase by Gilbert Cisneros on 28 January 2025.
What is the total disclosed congressional trading volume for LNTH?
Members of Congress have disclosed approximately $32K in LNTH purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in LNTH?
This LNTH page updates as soon as new STOCK Act disclosures are filed for Lantheus Holdings, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.